AMOT and fetal growth restriction: In IUGR-ECFCs vs. CTRL-ECFCs, we observed a decrease in expression of angiopoietin (−48%; p < 0.05) (Figure 7A), angiomotin (−31%; p < 0.05) (Figure 7B), vascular endothelial growth factor receptor-2 (VEGFR-2) (−42%; p < 0.05) (Figure 7C), and vascular endothelial growth factor-A (VEGF-A) (−41%; p < 0.05) (Figure 7D).